Bayer Aktiengesellscha Company Top Insiders

BAYZF Stock  USD 30.79  1.38  4.69%   
Bayer Aktiengesellscha employs about 102.3 K people. The company is managed by 53 executives with a total tenure of roughly 526 years, averaging almost 9.0 years of service per executive, having 1930.11 employees per reported executive. Examination of Bayer Aktiengesellscha's management performance can provide insight into the company performance.
Liam Condon  CEO
Member of Management Board and CEO of Bayer Cropscience
Patrick Thomas  CEO
CEO, Bayer MaterialScience
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bayer Aktiengesellschaft. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Bayer Aktiengesellscha Management Team Effectiveness

The company has return on total asset (ROA) of 0.0576 % which means that it generated a profit of $0.0576 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.13 %, meaning that it generated $0.13 on every $100 dollars invested by stockholders. Bayer Aktiengesellscha's management efficiency ratios could be used to measure how well Bayer Aktiengesellscha manages its routine affairs as well as how well it operates its assets and liabilities.

Bayer Aktiengesellscha Workforce Comparison

Bayer Aktiengesellschaft is number one stock in number of employees category among related companies. The total workforce of Drug Manufacturers—General industry is currently estimated at about 616,766. Bayer Aktiengesellscha retains roughly 102,296 in number of employees claiming about 17% of equities under Drug Manufacturers—General industry.
The company has Profit Margin (PM) of 0.09 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.23 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.23.

Bayer Aktiengesellschaft Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Bayer Aktiengesellschaft Price Series Summation is a cross summation of Bayer Aktiengesellscha price series and its benchmark/peer.

Bayer Aktiengesellscha Notable Stakeholders

A Bayer Aktiengesellscha stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bayer Aktiengesellscha often face trade-offs trying to please all of them. Bayer Aktiengesellscha's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bayer Aktiengesellscha's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Liam CondonMember of Management Board and CEO of Bayer CropscienceProfile
Patrick ThomasCEO, Bayer MaterialScienceProfile
Marijn DekkersChairman of Management Board and CEOProfile
Thomas WinVice Chairman of the Supervisory BoardProfile
Werner WenningChairman of the Supervisory BoardProfile
Jennifer BrendeltoVice President - Communications of the Consumer Health DivisionProfile
Wolfgang NicklCFO, Member of the Management BoardProfile
Johannes DietschCFO and Member of Management BoardProfile
Hartmut KlusikMember of the Management Board, Director of Human Resources, Technology & SustainabilityProfile
Oliver MaierHead RelationsProfile
Heiko SchipperMember of the Management Board, Head of the Consumer Health DivisionProfile
Thomas FischerMember of the Supervisory BoardProfile
Helmut PankeMember of the Supervisory BoardProfile
Reiner HoffmannMember of the Supervisory BoardProfile
Sue RatajMember of the Supervisory BoardProfile
Petra ReinboldKnapeMember of the Supervisory BoardProfile
Dieter WeinandMember of the Management Board and Head of the Pharmaceuticals Division, North America RegionProfile
Werner BaumannChief Strategy and Portfolio Officer and Member of Management BoardProfile
Sarena LinLabor OfficerProfile
Simone BagelTrahMember of the Supervisory BoardProfile
Michael SchmidtKiesslingMember of the Supervisory BoardProfile
ErnstLudwig WinnackerMember of the Supervisory BoardProfile
Colleen GogginsMember of the Supervisory BoardProfile
Heinz WebersMember of the Supervisory BoardProfile
Johanna FaberMember of the Supervisory BoardProfile
Frank LoellgenMember of the Supervisory BoardProfile
Andre BroichMember of the Supervisory BoardProfile
Rodrigo SantosMember DivisionProfile
Yueksel KaraaslanMember of the Supervisory BoardProfile
Erica MannMember of the Management Board, Head of the Consumer Health DivisionProfile
Norbert BischofbergerMember of the Supervisory BoardProfile
Michael KoenigMember of the Management Board responsible for Human ResourcesProfile
Heike HausfeldMember of the Supervisory BoardProfile
Peter HausmannMember of the Supervisory BoardProfile
Detlef RenningsMember of the Supervisory BoardProfile
Michael PreussGov CommunicationsProfile
Kemal MalikMember of Management Board, Chief Medical Officer of Bayer Healthcare and Head of Global Devel. - Bayer HealthcareProfile
Petra KronenMember of the Supervisory BoardProfile
Oliver ZuehlkeMember of the Supervisory BoardProfile
Thomas ElsnerMember of the Supervisory BoardProfile
Alexander RosarHead of Investor RelationsProfile
Paul AchleitnerMember of the Supervisory BoardProfile
Klaus SturanyIndependent Member of the Supervisory BoardProfile
Stefan OelrichMember of the Management Board, Head of the Pharmaceuticals DivisionProfile
Thomas EbelingMember of the Supervisory BoardProfile
Gabriel HarnierPatents LawProfile
Norbert WinkeljohannIndependent Member of the Supervisory BoardProfile
Clemens BoersigMember of the Supervisory BoardProfile
Juergen BeuninkInterim Head of Investor RelationsProfile
Otmar WiestlerMember of the Supervisory BoardProfile
Sabine SchaabMember of the Supervisory BoardProfile
BerndPeter BierHead TaxesProfile
Wolfgang PlischkeMember of the Supervisory BoardProfile

About Bayer Aktiengesellscha Management Performance

The success or failure of an entity such as Bayer Aktiengesellschaft often depends on how effective the management is. Bayer Aktiengesellscha management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bayer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bayer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany. Bayer Ag is traded on OTC Exchange in the United States.
The data published in Bayer Aktiengesellscha's official financial statements usually reflect Bayer Aktiengesellscha's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bayer Aktiengesellschaft. For example, before you start analyzing numbers published by Bayer accountants, it's critical to develop an understanding of what Bayer Aktiengesellscha's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Bayer Aktiengesellscha's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bayer Aktiengesellscha's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bayer Aktiengesellscha's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bayer Aktiengesellschaft. Please utilize our Beneish M Score to check the likelihood of Bayer Aktiengesellscha's management manipulating its earnings.

Bayer Aktiengesellscha Workforce Analysis

Traditionally, organizations such as Bayer Aktiengesellscha use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bayer Aktiengesellscha within its industry.

Bayer Aktiengesellscha Manpower Efficiency

Return on Bayer Aktiengesellscha Manpower

Revenue Per Employee430.9K
Revenue Per Executive831.7M
Net Income Per Employee9.8K
Net Income Per Executive18.9M
Working Capital Per Employee83K
Working Capital Per Executive160.2M
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bayer Aktiengesellschaft. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Bayer Aktiengesellschaft information on this page should be used as a complementary analysis to other Bayer Aktiengesellscha's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Bayer Pink Sheet analysis

When running Bayer Aktiengesellscha's price analysis, check to measure Bayer Aktiengesellscha's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bayer Aktiengesellscha is operating at the current time. Most of Bayer Aktiengesellscha's value examination focuses on studying past and present price action to predict the probability of Bayer Aktiengesellscha's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bayer Aktiengesellscha's price. Additionally, you may evaluate how the addition of Bayer Aktiengesellscha to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Please note, there is a significant difference between Bayer Aktiengesellscha's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bayer Aktiengesellscha is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bayer Aktiengesellscha's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.